Macular translocation is still effective after five years

Article

It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery..

According to data published in the journal Eye it is possible for AMD patients to maintain BCVA for five years after macular translocation surgery.

A team led by Dr K. Takeuchi, Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, assessed the medical records of 61 consecutive patients who experienced macular translocation.

Of the patients included in the study, 35 eyes were treated for AMD and 26 eyes were treated for myopic choroidal neovascularisation (mCNV). Area of the Goldmann visual field (VF) and BCVA were measured before surgery, 12 months after surgery and at the final follow-up.

In the AMD eyes the mean preoperative BCVA was 1.149±0.105 logMAR, improving to 0.69±0.06 logMAR 1 year postoperatively. The BCVA was maintained at 0.633±0.083 logMAR at the final follow-up visit.

In the mCNV eyes the mean preoperative BCVA was 1.083±0.119 logMAR, improving to 0.689±0.121 logMAR one year postoperatively. This was maintained at 0.678±0.142 logMAR at the final follow-up.

For both groups the area of the VF was significantly reduced at 12 months postoperatively and did not change significantly over the following five years.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.